SEC Filing Form 4 for Altimmune, Inc.

Richard Thomas Menziuso, Principal Accounting Officer of Altimmune, Inc., reported a transaction on October 1, 2026. This transaction involved acquiring 84,546 Stock Options and 36,234 Restricted Stock Units (RSUs). The stock options have an exercise price of $2.76 and vest over four years starting October 1, 2027, with 25% vesting on that date and the remainder vesting monthly over the following 36 months, subject to continued service. The RSUs also vest over four years, with 25% vesting on October 1, 2027, and the rest vesting annually over the subsequent three years, contingent upon continued service. Both the options and RSUs are directly owned and have post-transaction amounts reflecting the acquired shares.